Decreased Galectin-8 Is a Strong Marker for Recurrence in Urothelial Carcinoma of the Bladder

Kramer, Mario W.; Waalkes, Sandra; Serth, Jürgen; Hennenlotter, Jörg; Tezval, Hossein; Stenzl, Arnulf; Kuczyk, Markus A.; Merseburger, Axel S.

doi:10.1159/000328439

Cited by 26 publications

(16 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Remarkably, LGALS8 may serve as prognostic biomarkers in cancers. The expression level of LGALS8 is associated with recurrence of gastric cancer, urothelial carcinoma of the bladder and clear cell renal cell carcinoma . In glioma, LGALS8 enhances the capacities of proliferation and migration and inhibits apoptosis of GBM cells .…”

Section: Discussionmentioning

confidence: 99%

A risk signature with four autophagy‐related genes for predicting survival of glioblastoma multiforme

Wang

Zhao

Xiao

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is a devastating brain tumour without effective treatment. Recent studies have shown that autophagy is a promising therapeutic strategy for GBM. Therefore, it is necessary to identify novel biomarkers associated with autophagy in GBM. In this study, we downloaded autophagy-related genes from Human Autophagy Database (HADb) and Gene Set Enrichment Analysis (GSEA) website. Least absolute shrinkage and selection operator (LASSO) regression and multivariate Cox regression analysis were performed to identify genes for constructing a risk signature. A nomogram was developed by integrating the risk signature with clinicopathological factors. Time-dependent receiver operating characteristic (ROC) curve and calibration plot were used to evaluate the efficiency of the prognostic model. Finally, four autophagy-related genes (DIRAS3, LGALS8, MAPK8 and STAM)were identified and were used for constructing a risk signature, which proved to be an independent risk factor for GBM patients. Furthermore, a nomogram was developed based on the risk signature and clinicopathological factors (IDH1 status, age and history of radiotherapy or chemotherapy). ROC curve and calibration plot suggested the nomogram could accurately predict 1-, 3-and 5-year survival rate of GBM patients.For function analysis, the risk signature was associated with apoptosis, necrosis, immunity, inflammation response and MAPK signalling pathway. In conclusion, the risk signature with 4 autophagy-related genes could serve as an independent prognostic factor for GBM patients. Moreover, we developed a nomogram based on the risk signature and clinical traits which was validated to perform better for predicting 1-, 3-and 5-year survival rate of GBM. K E Y W O R D Sautophagy, glioblastoma multiform, nomogram, prognosis, risk signature

show abstract

Section: Discussionmentioning

confidence: 99%

A risk signature with four autophagy‐related genes for predicting survival of glioblastoma multiforme

Wang

Zhao

Xiao

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…By another hand, (over)expression of β-1-6GalNAc antennae, galectin-7, CD44v6, MUC2, MUC6, glycolipid enzyme GM3, and CD109 were linked to a less aggressive phenotype and/or better prognosis [ 32 , 104 , 121 , 122 , 129 , 199 , 213 ]. In turn, the loss of GnT-V, ABO(H) terminal structures, sLe a , Tn, galectin-8 and prostasin is associated with more aggressive cancer phenotypes, making them potential markers of poor prognosis [ 31 , 32 , 44 - 47 , 50 , 67 , 105 , 158 - 160 , 200 , 216 ]. Yet, glypican-3 tissue expression was not associated with aggressive phenotype nor prognosis [ 217 , 221 ] and studies for syndecan-1 demonstrated contradictory results [ 158 - 162 , 222 ], warranting elucidation of its prognostic and diagnostic role.…”

Section: Prognosis Glycomarkers For Bladder Cancermentioning

confidence: 99%

“…In succession, galectin-7 was pointed as a predictive marker of chemosensitivity to cisplatin in urothelial cancer [ 104 ]. Finally, the loss of galectin-8 in bladder tumours increases tumour recurrence, while decreased immunohistochemical staining is associated with higher tumour stage and grade [ 105 ]. As such, the loss of galectin-8 might be an early step in the development of malignant lesions of the bladder and is a significant independent predictor of recurrence [ 105 ].…”

Section: Introductionmentioning

confidence: 99%

Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?

et al. 2017

View full text Add to dashboard Cite

The high molecular heterogeneity of bladder tumours is responsible for significant variations in disease course, as well as elevated recurrence and progression rates, thereby hampering the introduction of more effective targeted therapeutics. The implementation of precision oncology settings supported by robust molecular models for individualization of patient management is warranted. This effort requires a comprehensive integration of large sets of panomics data that is yet to be fully achieved. Contributing to this goal, over 40 years of bladder cancer glycobiology have disclosed a plethora of cancer-specific glycans and glycoconjugates (glycoproteins, glycolipids, proteoglycans) accompanying disease progressions and dissemination. This review comprehensively addresses the main structural findings in the field and consequent biological and clinical implications. Given the cell surface and secreted nature of these molecules, we further discuss their potential for non-invasive detection and therapeutic development. Moreover, we highlight novel mass-spectrometry-based high-throughput analytical and bioinformatics tools to interrogate the glycome in the postgenomic era. Ultimately, we outline a roadmap to guide future developments in glycomics envisaging clinical implementation.

show abstract

“…The identified transcripts include proto‐oncogenes, proliferation activators, caveolins, and cell adhesion molecules . Also, a lower level of galectin‐8 in tumors as compared to the normal urothelium was described and proposed as a recurrence marker . Methylation changes in the promoter of RUNX3 were recently proposed as a predictor of tumor progression .…”

Section: Introductionmentioning

confidence: 99%

Prediction of recurrence of non muscle‐invasive bladder cancer by means of a protein signature identified by antibody microarray analyses

et al. 2014

View full text Add to dashboard Cite

About 70% of newly diagnosed cases of bladder cancer are low-stage, low-grade, non muscle-invasive. Standard treatment is transurethral resection. About 60% of the tumors will recur, however, and in part progress to become invasive. Therefore, surveillance cystoscopy is performed after resection. However, in the USA and Europe alone, about 54 000 new patients per year undergo repeated cystoscopies over several years, who do not experience recurrence. Analysing in a pilot study resected tumors from patients with (n = 19) and without local recurrence (n = 6) after a period of 5 years by means of an antibody microarray that targeted 724 cancer-related proteins, we identified 255 proteins with significantly differential abundance. Most are involved in the regulation and execution of apoptosis and cell proliferation. A multivariate classifier was constructed based on 20 proteins. It facilitates the prediction of recurrence with a sensitivity of 80% and a specificity of 100%. As a measure of overall accuracy, the area under the curve value was found to be 91%. After validation in additional sample cohorts with a similarly long follow-up, such a signature could support decision making about the stringency of surveillance or even different treatment options.

show abstract

Decreased Galectin-8 Is a Strong Marker for Recurrence in Urothelial Carcinoma of the Bladder

Cited by 26 publications

References 53 publications

A risk signature with four autophagy‐related genes for predicting survival of glioblastoma multiforme

A risk signature with four autophagy‐related genes for predicting survival of glioblastoma multiforme

Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?

Prediction of recurrence of non muscle‐invasive bladder cancer by means of a protein signature identified by antibody microarray analyses

Contact Info

Product

Resources

About